GCT 102
Alternative Names: GCT102Latest Information Update: 20 Mar 2026
At a glance
- Originator Kidswell Bio
- Developer Kidswell Bio; Mochida Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Gastrointestinal disorders
Most Recent Events
- 16 Mar 2026 Research development in Gastrointestinal-disorders is still ongoing (Parenteral) (Kidswell Bio pipeline, March 2026)
- 28 Apr 2024 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan (Parenteral)
- 01 Jul 2021 Gene Techno Science is now called Kidswell Bio